文献速递艾滋病与性传播感染

非洲病毒学抑制成人HIV感染者换用长效卡博特韦与利匹韦林(CARES):随机、多中心、开放标签、非劣效性试验第48周结果

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
PubMed 文献 · Lancet Infect Dis · 2024-05-28

CARES研究在乌干达、肯尼亚和南非8个中心纳入512例口服抗逆转录病毒治疗下HIV病毒载量低于50拷贝/mL且无病毒学失败史的成人,1:1随机换用每8周肌注卡博特韦600 mg与利匹韦林900 mg或继续口服治疗。第48周病毒载量低于50拷贝/mL者在长效组为246/255(96%)、口服组为250/257(97%),差异-0.8个百分点(95%CI -3.7至2.3),证实非劣效。

要点

  • 第48周病毒载量低于50拷贝/mL比例长效组96% vs 口服组97%,差异-0.8个百分点(95%CI -3.7至2.3),为非劣效。
  • 长效组2例病毒学失败且均伴耐药,口服组无病毒学失败。
  • 3级及以上不良事件长效组24例(9%)vs 口服组10例(4%),1例因注射部位反应停用长效治疗。

核心结论

  • 长效治疗疗效非劣于口服治疗,安全性良好,可考虑用于非洲治疗项目。

研究设计与样本

  • CARES为在乌干达、肯尼亚和南非8个中心开展的随机、开放标签、非劣效性试验,2021年9月1日至2022年8月31日纳入512例受试者(295例[58%]女性;380例[74%]既往暴露于非核苷类逆转录酶抑制剂)。
  • 受试者为口服抗逆转录病毒治疗下HIV病毒载量低于50拷贝/mL且无病毒学失败史者,1:1随机接受每8周肌注卡博特韦600 mg与利匹韦林900 mg或继续口服治疗,病毒载量每24周监测。
  • 主要结局为第48周病毒载量低于50拷贝/mL,采用美国食品药品监督管理局快照算法在意向治疗暴露人群中评估,非劣效界值为10个百分点;试验注册号Pan African Clinical Trials Registry 202104874490818,持续至96周。

主要发现

  • 第48周病毒载量低于50拷贝/mL者长效组246/255(96%)vs 口服组250/257(97%),差异-0.8个百分点(95%CI -3.7至2.3),证实非劣效,符合方案分析亦证实。
  • 长效组2例病毒学失败且均伴耐药,口服组无病毒学失败。
  • 3级及以上不良事件长效组24例(9%)vs 口服组10例(4%);1例因注射部位反应停用长效治疗。

关键数值与推荐

  • 非劣效界值为10个百分点,主要结局差异-0.8个百分点(95%CI -3.7至2.3)。
  • 长效治疗方案为卡博特韦600 mg与利匹韦林900 mg每8周肌内注射一次。

临床怎么用

  • 作者认为长效治疗疗效非劣于口服治疗且安全性良好,可考虑用于非洲治疗项目。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African treatment programmes where demographic factors, viral subtypes, previous treatment, and delivery and monitoring approaches differ. The aim of this study was to determine whether switching to long-acting therapy with injections every 8 weeks is non-inferior to daily oral therapy in Africa. METHODS: CARES is a randomised, open-label, non-inferiority trial being conducted at eight sites in Uganda, Kenya, and South Africa. Participants with HIV viral load below 50 copies per mL on oral antiretroviral therapy and no history of virological failure were randomly assigned (1:1; web-based, permuted blocks) to receive cabotegravir (600 mg) and rilpivirine (900 mg) by intramuscular injection every 8 weeks, or to continue oral therapy. Viral load was monitored every 24 weeks. The primary outcome was week 48 viral load below 50 copies per mL, assessed with the Food and Drug Administration snapshot algorithm (non-inferiority margin 10 percentage points) in the intention-to-treat exposed population. This trial is registered with the Pan African Clinical Trials Registry (202104874490818) and is ongoing up to 96 weeks. FINDINGS: Between Sept 1, 2021, and Aug 31, 2022, we enrolled 512 participants (295 [58%] female; 380 [74%] previous non-nucleoside reverse transcriptase inhibitor exposure). Week 48 viral load was below 50 copies per mL in 246 (96%) of 255 participants in the long-acting therapy group and 250 (97%) of 257 in the oral therapy group (difference -0·8 percentage points; 95% CI -3·7 to 2·3), demonstrating non-inferiority (confirmed in per-protocol analysis). Two participants had virological failure in the long-acting therapy group, both with drug resistance; none had virological failure in the oral therapy group. Adverse events of grade 3 or greater severity occurred in 24 (9%) participants on long-acting therapy and ten (4%) on oral therapy; one participant discontinued long-acting therapy (for injection-site reaction). INTERPRETATION: Long-acting therapy had non-inferior efficacy compared with oral therapy, with a good safety profile, and can be considered for African treatment programmes. FUNDING: Janssen.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kityo C, Mambule IK, Musaazi J, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024. PMID: 38821073. doi:10.1016/S1473-3099(24)00289-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。